NCT02355431 Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Status WITHDRAWN Phase PHASE2
NCT02327078 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Status COMPLETED Phase PHASE1/PHASE2
NCT02318277 A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) Status COMPLETED Phase PHASE1/PHASE2
NCT02298153 A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma Status TERMINATED Phase PHASE1
NCT02265510 An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Status TERMINATED Phase PHASE1/PHASE2
NCT02257619 Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT02252159 Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) Status COMPLETED Phase N/A
NCT02251821 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Status COMPLETED Phase PHASE2
NCT02178722 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Status COMPLETED Phase PHASE1/PHASE2
NCT02166905 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Status COMPLETED Phase PHASE1/PHASE2
NCT02155465 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Status COMPLETED Phase PHASE1/PHASE2
NCT02120417 A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Status TERMINATED Phase PHASE2
NCT02119650 Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT02118285 Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Status COMPLETED Phase PHASE1
NCT02117479 Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Status TERMINATED Phase PHASE3
NCT02093429 Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) Status TERMINATED Phase PHASE1/PHASE2
NCT02076191 Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Status COMPLETED Phase PHASE1/PHASE2